GlassScriptPhysician profile
Matthew R Peterson
NPI 1730475351
$4,279.16
in general payments reported to CMS, 2019-2025
44 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.22 · 2021: $19.74 · 2023: $836 · 2024: $1,823 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,131 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,131.20 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $474.28 | 2023-2025 | Calquence, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $418.81 | 2021-2025 | |
| Janssen Biotech, INC. | $333.00 | 2023-2025 | Darzalex, Tecvayli, Balversa |
| Celgene Corporation | $302.62 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Incyte Corporation | $224.50 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Gilead Sciences, INC. | $206.91 | 2023-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $186.90 | 2023-2025 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $185.34 | 2023-2025 | |
| Genzyme Corporation | $159.08 | 2023-2025 | |
| Pfizer INC. | $125.33 | 2024-2025 | |
| Lilly USA, LLC | $121.64 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $114.78 | 2024-2025 | Xospata, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $111.96 | 2023-2025 | Augtyro |
| Sobi, INC | $98.18 | 2023-2025 | |
| Glaxosmithkline, LLC. | $91.01 | 2024-2025 | Ojjaara |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $81.73 | 2024-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $77.84 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Eisai INC. | $64.42 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $64.26 | 2023-2025 | Fotivda |
| Array Biopharma INC | $64.10 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Geron Corporation | $63.60 | 2024-2025 | Rytelo |
| Daiichi Sankyo INC. | $54.78 | 2024 | Injectafer, Enhertu |
| Jazz Pharmaceuticals INC. | $52.56 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $52.26 | 2024-2025 | Sylvant |
| Takeda Pharmaceuticals U.S.A., INC. | $47.24 | 2023-2024 | Iclusig, Fruzaqla |
| Pharmaand Gmbh | $45.23 | 2025 | Rubraca |
| Caris Mpi, INC. | $44.25 | 2025 | Mi Cancer Seek |
| Pharmacosmos Therapeutics INC. | $44.09 | 2023-2024 | Monoferric |
| Stemline Therapeutics INC. | $42.83 | 2023-2024 | Elzonris, Orserdu |
| Puma Biotechnology, INC. | $42.82 | 2023-2024 | |
| Shield Therapeutics INC | $37.26 | 2025 | |
| Blueprint Medicines Corporation | $36.02 | 2024 | Ayvakit |
| Tolmar, INC. | $32.47 | 2025 | Eligard, Rubraca |
| Abbvie INC. | $31.34 | 2024-2025 | |
| Boston Scientific Corporation | $29.22 | 2019 | |
| Sumitomo Pharma America, INC. | $28.71 | 2025 | Orgovyx |
| Agios Pharmaceuticals, INC. | $22.21 | 2025 | Pyrukynd |
| Kerecis Limited | $18.30 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Adc Therapeutics America, INC. | $17.82 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $14.99 | 2023 | Imbruvica |
| Taiho Oncology, INC. | $14.47 | 2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.